|
1
|
Fang J, Zhou ZJ, Yuan S, Qiu Y, Ge XY. Lineage classification and selective site identification of Orthoebolavirus zairense. Microbes Infect 2025; 27:105304. [PMID: 38278475 DOI: 10.1016/j.micinf.2024.105304] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2023] [Revised: 01/19/2024] [Accepted: 01/21/2024] [Indexed: 01/28/2024]
Abstract
As the high pathogenic species of Filoviridae virus family, Orthoebolavirus zairense (EBOV) shows frequent outbreaks in human in recently years since its first emerging in 1976 in Democratic Republic of the Congo (COD), bringing ongoing risks and burden on public health safety. Here, the phylogenetic relationship among major outbreaks was analyzed. The results showed that EBOV isolates could be divided into four lineages according to spatial and temporal epidemics. Then, the positive selection sites (PSSs) were detected on all proteins of the EBOV, exhibiting lineage characteristic. Particularly, sites in GP and VP24 were identified to be significantly under positive selection, and partial of which were maintained in the latest isolates in 2021. GP and L were found to have high variability between lineages. Substitutions including F443L and F443S in GP, as well as F1610L and I1951V in L could be characteristic of the two large outbreaks in COD (2018) and West Africa (2014), respectively. Further, substitutions of significant PSSs in VP24 and L proteins were visualized for analysis of structural changes, which may affect EBOV pathogenesis. In summary, our results gains insights in genetic characteristic and adaptive evolution of EBOV, which could facilitate gene functional research against EBOV.
Collapse
Affiliation(s)
- Jie Fang
- Hunan Provincial Key Laboratory of Medical Virology, Institute of Pathogen Biology and Immunology, College of Biology, Hunan University, 27 Tianma Rd., Changsha, Hunan, 410012, China
| | - Zhi-Jian Zhou
- Hunan Provincial Key Laboratory of Medical Virology, Institute of Pathogen Biology and Immunology, College of Biology, Hunan University, 27 Tianma Rd., Changsha, Hunan, 410012, China
| | - Shuofeng Yuan
- Department of Microbiology, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China
| | - Ye Qiu
- Hunan Provincial Key Laboratory of Medical Virology, Institute of Pathogen Biology and Immunology, College of Biology, Hunan University, 27 Tianma Rd., Changsha, Hunan, 410012, China
| | - Xing-Yi Ge
- Hunan Provincial Key Laboratory of Medical Virology, Institute of Pathogen Biology and Immunology, College of Biology, Hunan University, 27 Tianma Rd., Changsha, Hunan, 410012, China.
| |
Collapse
|
|
2
|
Zumbrun EE, Garvey CB, Wells JB, Lynn GC, Van Tongeren SA, Steffens JT, Wetzel KS, Wetzel DL, Esham HL, Garza NL, Lee ED, Scruggs JL, Rossi FD, Brown ES, Weidner JM, Gomba LM, O’Brien KA, Jay AN, Zeng X, Akers KS, Kallgren PA, Englund E, Meinig JM, Kugelman JR, Moore JL, Bloomfield HA, Norris SL, Bryan T, Scheuerell CH, Walters J, Mollova N, Blair C, Babusis D, Cihlar T, Porter DP, Singh B, Hedskog C, Bavari S, Warren TK, Bannister R. A Randomized, Blinded, Vehicle-Controlled Dose-Ranging Study to Evaluate and Characterize Remdesivir Efficacy Against Ebola Virus in Rhesus Macaques. Viruses 2024; 16:1934. [PMID: 39772240 PMCID: PMC11680158 DOI: 10.3390/v16121934] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/26/2024] [Revised: 12/11/2024] [Accepted: 12/12/2024] [Indexed: 01/11/2025] Open
Abstract
Ebola virus (EBOV) causes severe disease in humans, with mortality as high as 90%. The small-molecule antiviral drug remdesivir (RDV) has demonstrated a survival benefit in EBOV-exposed rhesus macaques. Here, we characterize the efficacy of multiple intravenous RDV dosing regimens on survival of rhesus macaques 42 days after intramuscular EBOV exposure. Thirty rhesus macaques underwent surgical implantation of telemetry devices for the fine-scale monitoring of body temperature and activity, as well as central venous catheters, to enable treatment administration and blood collection. Treatment, consisting of a loading dose of RDV followed by once-daily maintenance doses for 11 days, was initiated 4 days after virus exposure when all animals were exhibiting disease signs consistent with incipient EBOV disease as well as quantifiable levels of EBOV RNA in plasma. In the RDV treatment groups receiving loading/maintenance doses of 5/2.5 mg/kg, 10/5 mg/kg, and 20/10 mg/kg, a total of 6 of 8 (75%), 7 of 8 (87.5%), and 5 of 7 (71.4%) animals survived, respectively. In the vehicle control group, one of seven animals (14.3%) survived. The improved survival rate compared to the control group was statistically significant only for the 10/5 mg/kg RDV treatment group. This treatment regimen also resulted in a significantly lower systemic viral load compared to the vehicle control after a single RDV treatment. All three RDV regimens produced a significantly lower systemic viral load after two treatments. For most animals, RDV treatment, regardless of dose, resulted in the amelioration of many of the clinical-pathological changes associated with EBOV disease in this model.
Collapse
Affiliation(s)
- Elizabeth E. Zumbrun
- United States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA; (C.B.G.); (J.B.W.); (G.C.L.); (S.A.V.T.); (J.T.S.); (K.S.W.); (D.L.W.); (H.L.E.); (E.D.L.); (J.L.S.); (F.D.R.); (E.S.B.); (J.M.W.); (L.M.G.); (K.A.O.); (A.N.J.); (X.Z.); (K.S.A.); (P.A.K.); (E.E.); (J.M.M.); (J.R.K.); (J.L.M.); (H.A.B.); (S.L.N.); (S.B.); (T.K.W.)
| | - Carly B. Garvey
- United States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA; (C.B.G.); (J.B.W.); (G.C.L.); (S.A.V.T.); (J.T.S.); (K.S.W.); (D.L.W.); (H.L.E.); (E.D.L.); (J.L.S.); (F.D.R.); (E.S.B.); (J.M.W.); (L.M.G.); (K.A.O.); (A.N.J.); (X.Z.); (K.S.A.); (P.A.K.); (E.E.); (J.M.M.); (J.R.K.); (J.L.M.); (H.A.B.); (S.L.N.); (S.B.); (T.K.W.)
- Geneva Foundation, Tacoma, WA 98402, USA
| | - Jay B. Wells
- United States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA; (C.B.G.); (J.B.W.); (G.C.L.); (S.A.V.T.); (J.T.S.); (K.S.W.); (D.L.W.); (H.L.E.); (E.D.L.); (J.L.S.); (F.D.R.); (E.S.B.); (J.M.W.); (L.M.G.); (K.A.O.); (A.N.J.); (X.Z.); (K.S.A.); (P.A.K.); (E.E.); (J.M.M.); (J.R.K.); (J.L.M.); (H.A.B.); (S.L.N.); (S.B.); (T.K.W.)
- Geneva Foundation, Tacoma, WA 98402, USA
| | - Ginger C. Lynn
- United States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA; (C.B.G.); (J.B.W.); (G.C.L.); (S.A.V.T.); (J.T.S.); (K.S.W.); (D.L.W.); (H.L.E.); (E.D.L.); (J.L.S.); (F.D.R.); (E.S.B.); (J.M.W.); (L.M.G.); (K.A.O.); (A.N.J.); (X.Z.); (K.S.A.); (P.A.K.); (E.E.); (J.M.M.); (J.R.K.); (J.L.M.); (H.A.B.); (S.L.N.); (S.B.); (T.K.W.)
- Geneva Foundation, Tacoma, WA 98402, USA
| | - Sean A. Van Tongeren
- United States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA; (C.B.G.); (J.B.W.); (G.C.L.); (S.A.V.T.); (J.T.S.); (K.S.W.); (D.L.W.); (H.L.E.); (E.D.L.); (J.L.S.); (F.D.R.); (E.S.B.); (J.M.W.); (L.M.G.); (K.A.O.); (A.N.J.); (X.Z.); (K.S.A.); (P.A.K.); (E.E.); (J.M.M.); (J.R.K.); (J.L.M.); (H.A.B.); (S.L.N.); (S.B.); (T.K.W.)
- Geneva Foundation, Tacoma, WA 98402, USA
| | - Jesse T. Steffens
- United States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA; (C.B.G.); (J.B.W.); (G.C.L.); (S.A.V.T.); (J.T.S.); (K.S.W.); (D.L.W.); (H.L.E.); (E.D.L.); (J.L.S.); (F.D.R.); (E.S.B.); (J.M.W.); (L.M.G.); (K.A.O.); (A.N.J.); (X.Z.); (K.S.A.); (P.A.K.); (E.E.); (J.M.M.); (J.R.K.); (J.L.M.); (H.A.B.); (S.L.N.); (S.B.); (T.K.W.)
- Geneva Foundation, Tacoma, WA 98402, USA
| | - Kelly S. Wetzel
- United States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA; (C.B.G.); (J.B.W.); (G.C.L.); (S.A.V.T.); (J.T.S.); (K.S.W.); (D.L.W.); (H.L.E.); (E.D.L.); (J.L.S.); (F.D.R.); (E.S.B.); (J.M.W.); (L.M.G.); (K.A.O.); (A.N.J.); (X.Z.); (K.S.A.); (P.A.K.); (E.E.); (J.M.M.); (J.R.K.); (J.L.M.); (H.A.B.); (S.L.N.); (S.B.); (T.K.W.)
- Geneva Foundation, Tacoma, WA 98402, USA
| | - Darrell L. Wetzel
- United States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA; (C.B.G.); (J.B.W.); (G.C.L.); (S.A.V.T.); (J.T.S.); (K.S.W.); (D.L.W.); (H.L.E.); (E.D.L.); (J.L.S.); (F.D.R.); (E.S.B.); (J.M.W.); (L.M.G.); (K.A.O.); (A.N.J.); (X.Z.); (K.S.A.); (P.A.K.); (E.E.); (J.M.M.); (J.R.K.); (J.L.M.); (H.A.B.); (S.L.N.); (S.B.); (T.K.W.)
| | - Heather L. Esham
- United States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA; (C.B.G.); (J.B.W.); (G.C.L.); (S.A.V.T.); (J.T.S.); (K.S.W.); (D.L.W.); (H.L.E.); (E.D.L.); (J.L.S.); (F.D.R.); (E.S.B.); (J.M.W.); (L.M.G.); (K.A.O.); (A.N.J.); (X.Z.); (K.S.A.); (P.A.K.); (E.E.); (J.M.M.); (J.R.K.); (J.L.M.); (H.A.B.); (S.L.N.); (S.B.); (T.K.W.)
| | - Nicole L. Garza
- United States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA; (C.B.G.); (J.B.W.); (G.C.L.); (S.A.V.T.); (J.T.S.); (K.S.W.); (D.L.W.); (H.L.E.); (E.D.L.); (J.L.S.); (F.D.R.); (E.S.B.); (J.M.W.); (L.M.G.); (K.A.O.); (A.N.J.); (X.Z.); (K.S.A.); (P.A.K.); (E.E.); (J.M.M.); (J.R.K.); (J.L.M.); (H.A.B.); (S.L.N.); (S.B.); (T.K.W.)
| | - Eric D. Lee
- United States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA; (C.B.G.); (J.B.W.); (G.C.L.); (S.A.V.T.); (J.T.S.); (K.S.W.); (D.L.W.); (H.L.E.); (E.D.L.); (J.L.S.); (F.D.R.); (E.S.B.); (J.M.W.); (L.M.G.); (K.A.O.); (A.N.J.); (X.Z.); (K.S.A.); (P.A.K.); (E.E.); (J.M.M.); (J.R.K.); (J.L.M.); (H.A.B.); (S.L.N.); (S.B.); (T.K.W.)
| | - Jennifer L. Scruggs
- United States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA; (C.B.G.); (J.B.W.); (G.C.L.); (S.A.V.T.); (J.T.S.); (K.S.W.); (D.L.W.); (H.L.E.); (E.D.L.); (J.L.S.); (F.D.R.); (E.S.B.); (J.M.W.); (L.M.G.); (K.A.O.); (A.N.J.); (X.Z.); (K.S.A.); (P.A.K.); (E.E.); (J.M.M.); (J.R.K.); (J.L.M.); (H.A.B.); (S.L.N.); (S.B.); (T.K.W.)
| | - Franco D. Rossi
- United States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA; (C.B.G.); (J.B.W.); (G.C.L.); (S.A.V.T.); (J.T.S.); (K.S.W.); (D.L.W.); (H.L.E.); (E.D.L.); (J.L.S.); (F.D.R.); (E.S.B.); (J.M.W.); (L.M.G.); (K.A.O.); (A.N.J.); (X.Z.); (K.S.A.); (P.A.K.); (E.E.); (J.M.M.); (J.R.K.); (J.L.M.); (H.A.B.); (S.L.N.); (S.B.); (T.K.W.)
| | - Elizabeth S. Brown
- United States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA; (C.B.G.); (J.B.W.); (G.C.L.); (S.A.V.T.); (J.T.S.); (K.S.W.); (D.L.W.); (H.L.E.); (E.D.L.); (J.L.S.); (F.D.R.); (E.S.B.); (J.M.W.); (L.M.G.); (K.A.O.); (A.N.J.); (X.Z.); (K.S.A.); (P.A.K.); (E.E.); (J.M.M.); (J.R.K.); (J.L.M.); (H.A.B.); (S.L.N.); (S.B.); (T.K.W.)
- Geneva Foundation, Tacoma, WA 98402, USA
| | - Jessica M. Weidner
- United States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA; (C.B.G.); (J.B.W.); (G.C.L.); (S.A.V.T.); (J.T.S.); (K.S.W.); (D.L.W.); (H.L.E.); (E.D.L.); (J.L.S.); (F.D.R.); (E.S.B.); (J.M.W.); (L.M.G.); (K.A.O.); (A.N.J.); (X.Z.); (K.S.A.); (P.A.K.); (E.E.); (J.M.M.); (J.R.K.); (J.L.M.); (H.A.B.); (S.L.N.); (S.B.); (T.K.W.)
- Geneva Foundation, Tacoma, WA 98402, USA
| | - Laura M. Gomba
- United States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA; (C.B.G.); (J.B.W.); (G.C.L.); (S.A.V.T.); (J.T.S.); (K.S.W.); (D.L.W.); (H.L.E.); (E.D.L.); (J.L.S.); (F.D.R.); (E.S.B.); (J.M.W.); (L.M.G.); (K.A.O.); (A.N.J.); (X.Z.); (K.S.A.); (P.A.K.); (E.E.); (J.M.M.); (J.R.K.); (J.L.M.); (H.A.B.); (S.L.N.); (S.B.); (T.K.W.)
- Geneva Foundation, Tacoma, WA 98402, USA
| | - Kristan A. O’Brien
- United States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA; (C.B.G.); (J.B.W.); (G.C.L.); (S.A.V.T.); (J.T.S.); (K.S.W.); (D.L.W.); (H.L.E.); (E.D.L.); (J.L.S.); (F.D.R.); (E.S.B.); (J.M.W.); (L.M.G.); (K.A.O.); (A.N.J.); (X.Z.); (K.S.A.); (P.A.K.); (E.E.); (J.M.M.); (J.R.K.); (J.L.M.); (H.A.B.); (S.L.N.); (S.B.); (T.K.W.)
- Geneva Foundation, Tacoma, WA 98402, USA
| | - Alexandra N. Jay
- United States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA; (C.B.G.); (J.B.W.); (G.C.L.); (S.A.V.T.); (J.T.S.); (K.S.W.); (D.L.W.); (H.L.E.); (E.D.L.); (J.L.S.); (F.D.R.); (E.S.B.); (J.M.W.); (L.M.G.); (K.A.O.); (A.N.J.); (X.Z.); (K.S.A.); (P.A.K.); (E.E.); (J.M.M.); (J.R.K.); (J.L.M.); (H.A.B.); (S.L.N.); (S.B.); (T.K.W.)
| | - Xiankun Zeng
- United States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA; (C.B.G.); (J.B.W.); (G.C.L.); (S.A.V.T.); (J.T.S.); (K.S.W.); (D.L.W.); (H.L.E.); (E.D.L.); (J.L.S.); (F.D.R.); (E.S.B.); (J.M.W.); (L.M.G.); (K.A.O.); (A.N.J.); (X.Z.); (K.S.A.); (P.A.K.); (E.E.); (J.M.M.); (J.R.K.); (J.L.M.); (H.A.B.); (S.L.N.); (S.B.); (T.K.W.)
| | - Kristen S. Akers
- United States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA; (C.B.G.); (J.B.W.); (G.C.L.); (S.A.V.T.); (J.T.S.); (K.S.W.); (D.L.W.); (H.L.E.); (E.D.L.); (J.L.S.); (F.D.R.); (E.S.B.); (J.M.W.); (L.M.G.); (K.A.O.); (A.N.J.); (X.Z.); (K.S.A.); (P.A.K.); (E.E.); (J.M.M.); (J.R.K.); (J.L.M.); (H.A.B.); (S.L.N.); (S.B.); (T.K.W.)
| | - Paul A. Kallgren
- United States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA; (C.B.G.); (J.B.W.); (G.C.L.); (S.A.V.T.); (J.T.S.); (K.S.W.); (D.L.W.); (H.L.E.); (E.D.L.); (J.L.S.); (F.D.R.); (E.S.B.); (J.M.W.); (L.M.G.); (K.A.O.); (A.N.J.); (X.Z.); (K.S.A.); (P.A.K.); (E.E.); (J.M.M.); (J.R.K.); (J.L.M.); (H.A.B.); (S.L.N.); (S.B.); (T.K.W.)
| | - Ethan Englund
- United States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA; (C.B.G.); (J.B.W.); (G.C.L.); (S.A.V.T.); (J.T.S.); (K.S.W.); (D.L.W.); (H.L.E.); (E.D.L.); (J.L.S.); (F.D.R.); (E.S.B.); (J.M.W.); (L.M.G.); (K.A.O.); (A.N.J.); (X.Z.); (K.S.A.); (P.A.K.); (E.E.); (J.M.M.); (J.R.K.); (J.L.M.); (H.A.B.); (S.L.N.); (S.B.); (T.K.W.)
| | - J. Matthew Meinig
- United States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA; (C.B.G.); (J.B.W.); (G.C.L.); (S.A.V.T.); (J.T.S.); (K.S.W.); (D.L.W.); (H.L.E.); (E.D.L.); (J.L.S.); (F.D.R.); (E.S.B.); (J.M.W.); (L.M.G.); (K.A.O.); (A.N.J.); (X.Z.); (K.S.A.); (P.A.K.); (E.E.); (J.M.M.); (J.R.K.); (J.L.M.); (H.A.B.); (S.L.N.); (S.B.); (T.K.W.)
| | - Jeffrey R. Kugelman
- United States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA; (C.B.G.); (J.B.W.); (G.C.L.); (S.A.V.T.); (J.T.S.); (K.S.W.); (D.L.W.); (H.L.E.); (E.D.L.); (J.L.S.); (F.D.R.); (E.S.B.); (J.M.W.); (L.M.G.); (K.A.O.); (A.N.J.); (X.Z.); (K.S.A.); (P.A.K.); (E.E.); (J.M.M.); (J.R.K.); (J.L.M.); (H.A.B.); (S.L.N.); (S.B.); (T.K.W.)
| | - Joshua L. Moore
- United States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA; (C.B.G.); (J.B.W.); (G.C.L.); (S.A.V.T.); (J.T.S.); (K.S.W.); (D.L.W.); (H.L.E.); (E.D.L.); (J.L.S.); (F.D.R.); (E.S.B.); (J.M.W.); (L.M.G.); (K.A.O.); (A.N.J.); (X.Z.); (K.S.A.); (P.A.K.); (E.E.); (J.M.M.); (J.R.K.); (J.L.M.); (H.A.B.); (S.L.N.); (S.B.); (T.K.W.)
| | - Holly A. Bloomfield
- United States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA; (C.B.G.); (J.B.W.); (G.C.L.); (S.A.V.T.); (J.T.S.); (K.S.W.); (D.L.W.); (H.L.E.); (E.D.L.); (J.L.S.); (F.D.R.); (E.S.B.); (J.M.W.); (L.M.G.); (K.A.O.); (A.N.J.); (X.Z.); (K.S.A.); (P.A.K.); (E.E.); (J.M.M.); (J.R.K.); (J.L.M.); (H.A.B.); (S.L.N.); (S.B.); (T.K.W.)
| | - Sarah L. Norris
- United States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA; (C.B.G.); (J.B.W.); (G.C.L.); (S.A.V.T.); (J.T.S.); (K.S.W.); (D.L.W.); (H.L.E.); (E.D.L.); (J.L.S.); (F.D.R.); (E.S.B.); (J.M.W.); (L.M.G.); (K.A.O.); (A.N.J.); (X.Z.); (K.S.A.); (P.A.K.); (E.E.); (J.M.M.); (J.R.K.); (J.L.M.); (H.A.B.); (S.L.N.); (S.B.); (T.K.W.)
| | - Tameka Bryan
- PharPoint Research, Inc., Wilmington, NC 28401, USA;
| | | | - Jesse Walters
- Labcorp Early Development Laboratories, Madison, WI 53704, USA; (C.H.S.); (J.W.)
| | - Nevena Mollova
- Gilead Sciences, Inc., Foster City, CA 94404, USA; (N.M.); (C.B.); (D.B.); (T.C.); (D.P.P.); (B.S.); (C.H.); (R.B.)
| | - Christiana Blair
- Gilead Sciences, Inc., Foster City, CA 94404, USA; (N.M.); (C.B.); (D.B.); (T.C.); (D.P.P.); (B.S.); (C.H.); (R.B.)
| | - Darius Babusis
- Gilead Sciences, Inc., Foster City, CA 94404, USA; (N.M.); (C.B.); (D.B.); (T.C.); (D.P.P.); (B.S.); (C.H.); (R.B.)
| | - Tomas Cihlar
- Gilead Sciences, Inc., Foster City, CA 94404, USA; (N.M.); (C.B.); (D.B.); (T.C.); (D.P.P.); (B.S.); (C.H.); (R.B.)
| | - Danielle P. Porter
- Gilead Sciences, Inc., Foster City, CA 94404, USA; (N.M.); (C.B.); (D.B.); (T.C.); (D.P.P.); (B.S.); (C.H.); (R.B.)
| | - Bali Singh
- Gilead Sciences, Inc., Foster City, CA 94404, USA; (N.M.); (C.B.); (D.B.); (T.C.); (D.P.P.); (B.S.); (C.H.); (R.B.)
| | - Charlotte Hedskog
- Gilead Sciences, Inc., Foster City, CA 94404, USA; (N.M.); (C.B.); (D.B.); (T.C.); (D.P.P.); (B.S.); (C.H.); (R.B.)
| | - Sina Bavari
- United States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA; (C.B.G.); (J.B.W.); (G.C.L.); (S.A.V.T.); (J.T.S.); (K.S.W.); (D.L.W.); (H.L.E.); (E.D.L.); (J.L.S.); (F.D.R.); (E.S.B.); (J.M.W.); (L.M.G.); (K.A.O.); (A.N.J.); (X.Z.); (K.S.A.); (P.A.K.); (E.E.); (J.M.M.); (J.R.K.); (J.L.M.); (H.A.B.); (S.L.N.); (S.B.); (T.K.W.)
| | - Travis K. Warren
- United States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA; (C.B.G.); (J.B.W.); (G.C.L.); (S.A.V.T.); (J.T.S.); (K.S.W.); (D.L.W.); (H.L.E.); (E.D.L.); (J.L.S.); (F.D.R.); (E.S.B.); (J.M.W.); (L.M.G.); (K.A.O.); (A.N.J.); (X.Z.); (K.S.A.); (P.A.K.); (E.E.); (J.M.M.); (J.R.K.); (J.L.M.); (H.A.B.); (S.L.N.); (S.B.); (T.K.W.)
- Geneva Foundation, Tacoma, WA 98402, USA
| | - Roy Bannister
- Gilead Sciences, Inc., Foster City, CA 94404, USA; (N.M.); (C.B.); (D.B.); (T.C.); (D.P.P.); (B.S.); (C.H.); (R.B.)
| |
Collapse
|
|
4
|
Collados Rodríguez M, Maillard P, Journeaux A, Komarova AV, Najburg V, David RYS, Helynck O, Guo M, Zhong J, Baize S, Tangy F, Jacob Y, Munier-Lehmann H, Meurs EF. Novel Antiviral Molecules against Ebola Virus Infection. Int J Mol Sci 2023; 24:14791. [PMID: 37834238 PMCID: PMC10573436 DOI: 10.3390/ijms241914791] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2023] [Revised: 09/19/2023] [Accepted: 09/22/2023] [Indexed: 10/15/2023] Open
Abstract
Infection with Ebola virus (EBOV) is responsible for hemorrhagic fever in humans with a high mortality rate. Combined efforts of prevention and therapeutic intervention are required to tackle highly variable RNA viruses, whose infections often lead to outbreaks. Here, we have screened the 2P2I3D chemical library using a nanoluciferase-based protein complementation assay (NPCA) and isolated two compounds that disrupt the interaction of the EBOV protein fragment VP35IID with the N-terminus of the dsRNA-binding proteins PKR and PACT, involved in IFN response and/or intrinsic immunity, respectively. The two compounds inhibited EBOV infection in cell culture as well as infection by measles virus (MV) independently of IFN induction. Consequently, we propose that the compounds are antiviral by restoring intrinsic immunity driven by PACT. Given that PACT is highly conserved across mammals, our data support further testing of the compounds in other species, as well as against other negative-sense RNA viruses.
Collapse
Affiliation(s)
- Mila Collados Rodríguez
- School of Infection & Immunity (SII), College of Medical, Veterinary and Life Sciences (MVLS), Sir Michael Stoker Building, MRC-University of Glasgow Centre for Virus Research (CVR), Glasgow G61 1QH, UK
- Unité Hépacivirus et Immunité Innée, CNRS, UMR 3569, Département de Virologie, Institut Pasteur, 75015 Paris, France; (P.M.); (E.F.M.)
| | - Patrick Maillard
- Unité Hépacivirus et Immunité Innée, CNRS, UMR 3569, Département de Virologie, Institut Pasteur, 75015 Paris, France; (P.M.); (E.F.M.)
| | - Alexandra Journeaux
- Unit of Biology of Emerging Viral Infections, Institut Pasteur, 69007 Lyon, France; (A.J.); (S.B.)
| | - Anastassia V. Komarova
- Interactomics, RNA and Immunity Laboratory, Institut Pasteur, 75015 Paris, France;
- Unité de Génomique Virale et Vaccination, Institut Pasteur, 75015 Paris, France; (V.N.); (R.-Y.S.D.); (F.T.)
- Université Paris Cité, 75013 Paris, France;
| | - Valérie Najburg
- Unité de Génomique Virale et Vaccination, Institut Pasteur, 75015 Paris, France; (V.N.); (R.-Y.S.D.); (F.T.)
- Université Paris Cité, 75013 Paris, France;
| | - Raul-Yusef Sanchez David
- Unité de Génomique Virale et Vaccination, Institut Pasteur, 75015 Paris, France; (V.N.); (R.-Y.S.D.); (F.T.)
- Blizard Institute—Faculty of Medicine and Dentistry, Queen Mary University of London, London E1 2AT, UK
| | - Olivier Helynck
- Unité de Chimie et Biocatalyse, CNRS, UMR 3523, Institut Pasteur, Université de Paris, 75015 Paris, France; (O.H.); (H.M.-L.)
| | - Mingzhe Guo
- CAS Key Laboratory of Molecular Virology and Immunology, Unit of Viral Hepatitis, Shanghai Institute of Immunity and Infection, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Shanghai 200023, China; (M.G.); (J.Z.)
| | - Jin Zhong
- CAS Key Laboratory of Molecular Virology and Immunology, Unit of Viral Hepatitis, Shanghai Institute of Immunity and Infection, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Shanghai 200023, China; (M.G.); (J.Z.)
| | - Sylvain Baize
- Unit of Biology of Emerging Viral Infections, Institut Pasteur, 69007 Lyon, France; (A.J.); (S.B.)
| | - Frédéric Tangy
- Unité de Génomique Virale et Vaccination, Institut Pasteur, 75015 Paris, France; (V.N.); (R.-Y.S.D.); (F.T.)
- Université Paris Cité, 75013 Paris, France;
| | - Yves Jacob
- Université Paris Cité, 75013 Paris, France;
- Unité Génétique Moléculaire des Virus à ARN, CNRS, UMR 3569, Département de Virologie, Institut Pasteur, 75015 Paris, France
| | - Hélène Munier-Lehmann
- Unité de Chimie et Biocatalyse, CNRS, UMR 3523, Institut Pasteur, Université de Paris, 75015 Paris, France; (O.H.); (H.M.-L.)
| | - Eliane F. Meurs
- Unité Hépacivirus et Immunité Innée, CNRS, UMR 3569, Département de Virologie, Institut Pasteur, 75015 Paris, France; (P.M.); (E.F.M.)
| |
Collapse
|
|
6
|
Hussein HA. Brief review on ebola virus disease and one health approach. Heliyon 2023; 9:e19036. [PMID: 37600424 PMCID: PMC10432691 DOI: 10.1016/j.heliyon.2023.e19036] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2022] [Revised: 07/31/2023] [Accepted: 08/07/2023] [Indexed: 08/22/2023] Open
Abstract
Ebola virus disease (EVD) is a severe and highly fatal zoonotic disease caused by viruses in the family Filoviridae and genus Ebolavirus. The disease first appeared in Zaire near the Ebola River in 1976, now in the Democratic Republic of the Congo. Since then, several outbreaks have been reported in different parts of the world, mainly in Africa, leading to the identification of six distinct viral strains that cause disease in humans and other primates. Bats are assumed to be the main reservoir hosts of the virus, and the initial incidence of human epidemics invariably follows exposure to infected forest animals through contact or consumption of bush meat and body fluids of forest animals harboring the disease. Human-to-human transmission occurs when contaminated body fluids, utensils, and equipment come in contact with broken or abraded skin and mucous membranes. EVD is characterized by sudden onset of 'flu-like' symptoms (fever, myalgia, chills), vomiting and diarrhea, then disease rapidly evolves into a severe state with a rapid clinical decline which may lead potential hemorrhagic complications and multiple organ failure. Effective EVD prevention, detection, and response necessitate strong coordination across the animal, human, and environmental health sectors, as well as well-defined roles and responsibilities evidencing the significance of one health approach; the natural history, epidemiology, pathogenesis, and diagnostic procedures of the Ebola virus, as well as prevention and control efforts in light of one health approach, are discussed in this article.
Collapse
Affiliation(s)
- Hassan Abdi Hussein
- College of Veterinary Medicine, Department of One Health Tropical Infectious Disease, Jigjiga University, P.O. Box: 1020, Jigjiga, Ethiopia
| |
Collapse
|